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Vascular calcifications bear the risk for cardiovascular complications and have a high prevalence among patients with chronic
kidney disease. Central mediators of vascular calcifications are vascular smooth muscle cells (VSMC). They transdifferentiate into
a synthetic/osteoblast-like phenotype, which is induced, for example, by elevated levels of calcium and phosphate (Ca/P) due to
a disturbed mineral balance. An aqueous extract from Lindera obtusiloba (LOE) is known to exert antifibrotic and antitumor
effects or to interfere with the differentiation of preadipocytes. Using murine and rat VSMC cell lines, we here investigated whether
LOE also protects VSMC from Ca/P-induced calcification. Indeed, LOE effectively blocked Ca/P-induced calcification of VSMC as
shown by decreased VSMCmineralization and secretion of alkaline phosphatase. In parallel, mRNA expression of the calcification
markers osterix and osteocalcin was reduced. Vice versa, the Ca/P-induced loss of the VSMC differentiation markers alpha smooth
muscle actin and smoothmuscle protein 22-alphawas rescued by LOE. Further, LOE blockedCa/P-inducedmRNAexpressions and
secretions of matrix metalloproteinases-2/-9 and activation of NF-𝜅B, which are known contributors to vascular calcification. In
conclusion, LOE interferes with theCa/P-induced transdifferentiation/calcification ofVSMC.Thus, LOE should be further analysed
regarding a potential complementary treatment option for cardiovascular diseases including vascular calcifications.
1. Introduction
Among patients with chronic kidney disease (CKD), cardio-
vascular complications are the leading cause of death [1].
Thus, most CKD patients die because of a systemic damage
of the cardiovascular system. The formation of vascular
calcifications in vessels or the heart plays an important
role and is of vital importance for the life expectancy of
dialysis patients [2]. During the onset of arterial calcifica-
tions, vascular smooth muscle cells (VSMC) in the media
transdifferentiate from a quiescent/contractile phenotype to
a synthetic/osteoblast-like phenotype [3]. As of today, there
is no established therapy for the inhibition of onset and
progression of vascular calcification.
Compositions or mixtures of medicinal plants are tradi-
tionally used to prevent or treat certain diseases like cancer
or liver diseases [4, 5]. In traditional Chinese and Korean
medicine, preparations from the medicinal plant Lindera
obtusiloba are applied to treat inflammations and to improve
blood circulation [6]. A drinkable aqueous extract from
Lindera obtusiloba (LOE) comprises a good physiological
compatibility and was previously shown to exert beneficial
effects in models of adipogenesis, liver fibrosis, and liver
cancer [7–9]. So far, identified bioactive compounds from
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LOE are, for example, polyphenols like (+)-episesamin [10],
the antioxidant compound quercitrin [11], and substances
which belong to the group of lignans and butenolides [12, 13].
The traditional effects on blood circulation [6] along with
antioxidative and anti-inflammatory effects of LOE [7–9] led
us to the hypothesis that LOE might exert preventive effects
also in models of vascular calcification.
To investigate this issue, we used an established in vitro
model of vascular calcification which enables the induction
of calcification/transdifferentiation of VSMC with elevated
concentrations of calcium and phosphorus (Ca/P) [14].
2. Materials and Methods
2.1. Preparation and Standardization of the Lindera obtusiloba
Extract. Freeze-dried extracts of Lindera obtusiloba were
obtained as described previously [9]. To obtain stock solu-
tions, 10mg powder was dissolved in 10mL sterile distilled
water at 60∘C for 30min. Aliquots were stored at −20∘C.
Freshly prepared working solutions of L. obtusiloba extract
were routinely tested/standardized as described [8, 9] before
being used in the respective calcification experiments.
2.2. Cell Culture. The murine VSMC cell lines (MOVAS-
1; ATCC CRL-2797 and human aortic VSMC) (Life Tech-
nologies, Karlsruhe, Germany) were cultured in a humidified
atmosphere at 37∘C and 5% CO
2
. Standard culture medium
consisted of DMEM with 862mg/L L-alanyl-L-glutamine,
1.0 g/L glucose, 50𝜇g/mL streptomycin, 50 units/mL peni-
cillin, and 0.2mg/mL G418, supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Biochrom, Berlin, Ger-
many). Cell layers were detached with 0.05% trypsin/0.02%
EDTA solution (Biochrom). Cells were maintained at 70–
80% confluence by passaging as needed. Human VSMC were
used from passages 5 to 12.
2.3. Induction of VSMC Calcification. VSMC were grown
in 24-well plates (Becton Dickinson, Heidelberg, Germany)
until they were ∼90% confluent (day 0). The culture medium
was then replaced by calcification medium (Ca/P) which
consists of standard culture medium supplemented with
calcium chloride (2.7mM versus 1.8mM) and sodium dihy-
drogen phosphate (2.8mM versus 1.0mM). VSMCwere then
cultured under the different treatment conditions for 9-10
days as indicated. Media were replaced every second day.
2.4. Analysis of VSMC Calcification. At the end of the treat-
ment, the cells were washed three times with calcium-free
PBS and decalcified with 0.1M HCl for 30min. Calcium
content in the supernatant was determined by the o-cres-
olphthalein complexone (OCPC) method as described [14].
Calcium contents were normalized to the protein contents
of the lysates which were determined by the BCA method
according to the manufacturer’s instructions (Thermo Fisher
Scientific, Waltham, MA, USA).
In addition, alizarin red staining of mineralized VSMC
was performed. At the end of the treatment, the cells were
fixed with 4% paraformaldehyde for 10min and washed with
distilled water before the incubation with 2% alizarin red
solution. After 30min on a rotary shaker, wells were washed
three times with equal volumes of distilled water. Pho-
tographs were taken by a digital microscope (Keyence, Neu-
Isenburg, Germany). Alizarin red staining was quantified by
resolving bound alizarin red dye with 2.5% cetylpyridinium
chloride and photometric measurement of absorbance at
540 nm using an ELISA reader (Biorad, Munich, Germany).
As a characteristic marker of vascular calcification, the
content of alkaline phosphatase (ALP) inVSMC supernatants
was analyzed with the Quanti Blue reagent (InvivoGen, San
Diego, CA, USA) as described [14].
2.5. Quantitative Real-Time Reverse Transcription-Polymerase
Chain Reaction (RT-PCR). VSMC in 6-well tissue culture
plates at ∼90% confluency were serum starved for 24 h in
standard culture medium containing 0.2% FBS. Cells were
then treated for 24 h as indicated. Total RNA was isolated
and transcribed into complementary DNA (cDNA) with
the RNeasy Mini Kit (Quiagen, Hilden, Germany) and the
High Capacity RNA to DNA kit (Applied Biosystems, Foster
City, CA, USA), respectively. Quantitative PCR using SYBR
Green Master Mix (Applied Biosystems) was performed
on MxPro-system from Stratagene (Agilent Technologies,
Santa Clara, CA, USA). The relative amount of RNA was
calculated using the 2−ΔΔCtmethod andnormalized tomRNA
expressions of the housekeeping genes YWAHZ (tyrosine
3-monooxygenase/tryptophan 5-monooxygenase activation
protein, zeta polypeptide) or HPRT (hypoxanthine phospho-
ribosyltransferase). The primer sequences used are available
on demand. All measurements were performed in triplicate.
2.6. Measurement of Effects of LOE on VSMC Viability.
Cell cycle synchronized VSMC were treated with different
concentrations of LOE for 24–48 h and viable cells were
detected as described by conversion of the fluorescent dye
calcein AM by intracellular esterase [7].
2.7. Determination of MMP-Activity in VSMC Supernatants.
Enzymatic activities of MMP-2 and MMP-9 were mea-
sured by cleavage of 0.01mg/mL dye-quenched DQ-gelatin
(Molecular Probes) as described [15]. Cells were treated as
mentioned above for calcification. At the indicated time
points, the medium was replaced by serum-free growth
medium for 16 h. 50𝜇L of the supernatants was transferred
to a black 96-well microtiter plate with clear bottom (Greiner
Bio-One). Each well received 150 𝜇L DQ-gelatin solution and
fluorescence signals weremonitored for 140min at 37∘Cusing
a Victor3 microplate reader (Perkin Elmer). Background
subtraction was applied to all measurements.
2.8. Measurement of NF-𝜅B Activation in VSMC. For the
luciferase reporter assay experiments, VSMC were tran-
siently transfected in white 96-well plates (NUNC, Roskilde,
Denmark) with reporter plasmids for the NF-𝜅B pathway
(pGL4.32[luc2P/NF-𝜅B-RE/Hygro]) and a Renilla vector
(pGL4.74[hRluc/TK]) for normalization of transfection effi-
ciencies. Transfections were performed using the FuGENE












































Figure 1: LOE attenuates Ca/P-induced VSMC mineralization. VSMC were cultured as indicated for 9 d. Shown are representative images
of alizarin red stained murine (a) and human (b) VSMC together with the respective quantification of bound alizarin red dye from four
independent experiments. Shown are means ± SD. ∗𝑃 ≤ 0.05, ∗∗𝑃 ≤ 0.01.
HD Transfection Reagent (Promega, Mannheim, Germany)
according to the manufacturer’s instructions. 24 h after
transfection, the cells were treated as indicated for 24 h
and analysed using the Dual-Glo Luciferase Assay System
(Promega) according to themanufacturer’s instructions using
a Victor3 microplate reader (Perkin Elmer).
2.9. Statistical Analyses. One-way ANOVA followed by the
Tukey post hoc test was used to analyse the datasets using
GraphPad PRISM, version 6.01 (GraphPad Software, USA),
and differences with 𝑃 values ≤0.05/≤0.01/≤0.001 (∗/ ∗ ∗/ ∗
∗∗) were considered to be statistically significant.
3. Results
3.1. LOE Attenuates Ca/P-Induced Calcification in
VSMC. VSMC treated with standard culture medium
(1.03mMPO4
3−; 1.0mMCa2+) exhibited no calcifications
whereas VSMC treated with calcification medium
(2.8mMPO4
3−; 2.7mMCa2+; Ca/P) showed a strong de-
gree of calcification after 9 d as shown by enhanced alizarin
red staining in murine (Figure 1(a)) and human VSMC
(Figure 1(b)), respectively. In the presence of LOE these
calcifications were distinctly decreased.
These data were confirmed by measurements of calcium
amounts in the respective VSMC cultures and the release
of alkaline phosphatase (ALP) into the VSMC supernatants.
While the calcification medium caused a strong upregulation
of both parameters in murine (Figure 2(a)) and human
VSMC (Figure 2(b)), LOE almost neutralized the stimulating
effects of the calcification medium on calcium accumulation
and ALP secretion.
3.2.The Attenuating Effects of LOE on VSMCCalcification Are
Not due to Cytotoxicity. Thepreceding data showed that LOE
reduced calcification in VSMC. To ensure that these effects
are not due to cytotoxic effects, equal LOE concentrations
were tested in cytotoxicity assays in VSMC. Figure 3 shows
that even the highest LOE concentration of 150𝜇g/mLdid not
significantly affect the viability of murine (Figure 3(a)) and
human VSMC (Figure 3(b)).
3.3. LOE Blocks CalcificationMedium-InducedmRNA Expres-
sions of Osterix and Osteocalcin in VSMC. To gain insights
into processes on molecular levels, treatment dependent
changes inmRNAexpression levels of the typical calcification
markers osterix and osteocalcin were determined in murine
VSMC. As shown in Figure 4(a), the calcification medium
induced a strong upregulation of osterix and osteocalcin
mRNA expressions, which was attenuated by cotreatment
with LOE. In addition, we investigated effects of LOE on
the expression levels of typical markers of the differentiated,
contractile VSMC phenotype. As expected, Ca/P-treated
VSMC exhibited distinctly reduced expression levels of alpha
smooth muscle actin (𝛼-SMA) and smooth muscle protein
22-alpha (SM22𝛼) (Figure 4(b)). However, cotreatment with
150 𝜇g/mL LOE prevented VSMC from reduced expressions
levels of 𝛼-SMA and SM22𝛼 (Figure 4(b)).
3.4. LOE Attenuates Ca/P-Induced mRNA Expressions of
MMP-2 and MMP-9 and Gelatinolytic Activities in VSMC
Supernatants. Enhanced proteolytic activity by matrix met-
alloproteinases has been shown to promote vascular calcifica-
tion and LOE is known to exert inhibitory effects on MMPs.
We therefore analysed if LOE impacts the Ca/P-induced
expression of the gelatinases MMP-2 and MMP-9 by murine
VSMC. As expected, Ca/P-treated VSMC exhibited mRNA
upregulations of both MMPs after 24–48 h (Figure 5(a)).
In contrast to the MMP-2 mRNA expression which shows
a slight and steady increase at 24 h and 48 h, the mRNA
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Figure 2: Effects of LOE on Ca/P-induced VSMC calcification and production of alkaline phosphatase. Calcium contents and alkaline
phosphatase (ALP) amounts in supernatants served as additional markers of VSMC calcification. Shown are treatment dependent effects
on calcium and ALP levels in murine (a) and human VSMC (b) (𝑛 = 4; mean ± SD; ∗∗𝑃 ≤ 0.01, ∗∗∗𝑃 ≤ 0.001).




































Figure 3: Effects of LOE on the viability of VSMC. Cell viability of murine (a) and human (b) VSMC was quantified fluorometrically after
24–48 h treatment with different concentrations of LOE by intracellular esterase-mediated conversion of calcein AM and was calculated in
relation to vehicle treated cells (100%). Shown are means ± SD (𝑛 = 3; nsnot significant).
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Figure 4: Effects of LOE on Ca/P-induced mRNA expressions of osterix, osteocalcin, 𝛼-SMA, and SM22𝛼. The mRNA expressions of osterix
and osteocalcin (𝑛 = 3) (a) and of 𝛼-SMA and SM22𝛼 (𝑛 = 4) (b) in murine VSMC were determined by RT-PCR. The expression pattern
after 24 h of stimulation is shown (means ± SD; nsnot significant; ∗𝑃 ≤ 0.05; ∗∗𝑃 ≤ 0.01; ∗∗∗𝑃 = 0.001).
expression of MMP-9 reaches a maximum after 24 h and is
almost reduced to the basal level after 48 h. In the presence
of LOE, the Ca/P-induced increased mRNA expressions
of MMP-2 as well as of MMP-9 were neutralized to the
expression level of the control at each time point.
In parallel, experiments which detect treatment depen-
dent gelatinolytic activities in supernatants from VSMCwere
performed. LOE distinctly reduced the elevated gelatinolytic
activities in aliquots of serum-free supernatants which were
incubated with the differently treated VSMC. Figure 5(b)
shows one representative result out of three experiments and
Figure 5(c) shows a summary of respective endpoints from
three independent experiments.
3.5. LOE Reduces the Activation of the Transcription Factor
NF-𝜅B by Ca/P in VSMC. The expression levels of MMPs
in VSMC are regulated by the transcription factor NF-𝜅B.
We therefore studied if LOE is capable of decreasing the
activation of NF-𝜅B by Ca/P. As shown in Figure 6, LOE
indeed effectively blocked an increase of NF-𝜅B activation
after treatment of murine VSMC with the calcification
medium.
4. Discussion
We here provide evidence that an aqueous extract from
the medicinal plant Lindera obtusiloba (LOE) protects
VSMC from artificial induced calcifications by a calcification
medium (containing elevated levels of calcium and phospho-
rus).
A disturbed balance of minerals is a common feature
of cardiovascular diseases associated with CKD. Elevated
plasma levels of calcium and phosphorus contribute to the
induction of VSMC transdifferentiation which represents an
underlying step in the development of vascular calcifications.
To screen potential inhibitors of vascular calcification,
this transdifferentiation of VSMC can be mimicked or
induced in vitro by elevated concentrations of calcium
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Figure 5: Effects of LOE on Ca/P-induced mRNA expression of MMP-2 and MMP-9 and gelatinolytic activities in VSMC supernatants. (a)
Shown are the treatment dependent mRNA expression levels of MMP-2 and MMP-9 in murine VSMC after 24–48 h (𝑛 = 3). (b) Shown is a
representative result of onemeasurement of gelatinolytic activities inVSMC supernatants by cleavage ofDQ-gelatin and (c) the corresponding
means ± SD of the respective endpoints of three independent measurements (nsnot significant; ∗∗𝑃 ≤ 0.01, ∗∗∗𝑃 ≤ 0.001).
and phosphorus [16]. In our experiments, the calcification
medium-treatedVSMC exhibited strong signs of calcification
as demonstrated by enhanced alizarin red staining and
elevated calcium contents inVSMCcultures and also elevated
levels of alkaline phosphatase in VSMC supernatants. All
these effects were strongly reduced by cotreatment with LOE.
This clearly suggests protective effects of LOE on calcification
of VSMC.
On a molecular level, an early step of VSMC trans-
differentiation is the upregulation of bone differentiation
markers which are commonly used as markers to indicate the
phenotypic conversion of VSMC to osteoblast-like cells [17–
21]. As shown here, LOE effectively decreased calcification
medium-induced upregulation of osterix and osteocalcin
mRNA expression. In conjunction with the here shown
protective effects of LOE against Ca/P-induced loss of mRNA
expressions of 𝛼-SMA and of SM22𝛼, our data indicate
that LOE prevents VSMC from calcium-/phosphate-induced
transdifferentiation, thereby preventing VSMC calcifications.
As previously also shown in other cell types [7, 9], LOE
decreased the mRNA expression and enzymatic activity of
the gelatinases MMP-2 and MMP-9 in VSMC. Both MMPs
were shown to promote vascular calcifications associated
with CKD [22, 23]. They are believed to induce proteolytic
remodelling of the extracellular (vessel) matrix and thereby
are supposed to generate biologically active matrix fragments
which might amplify the process of VSMC calcification
[24, 25]. These effects of MMPs on vascular calcification
Evidence-Based Complementary and Alternative Medicine 7
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Figure 6: Effects of LOE on Ca/P-induced activation of NF-𝜅B
in VSMC. Treatment dependent changes in luciferase activity as
an indicator for activation or inhibition of NF-𝜅B were detected
in murine VSMC after 24 h. Shown are means ± SD of three
independent measurements. ∗∗𝑃 ≤ 0.01, ∗∗∗𝑃 ≤ 0.001.
could be blocked by pharmacological inhibition of MMPs
[26, 27]. LOE was previously shown to reduce the secretion
of gelatinases by preadipocytes and the enzymatic activity
of recombinant MMP-2 [9]. In combination with the here
shown interference of LOE with Ca/P-induced transcription
in VSMC and gelatinolytic activity in VSMC supernatants,
these data suggest that MMPs represent an important target
of LOE in the inhibition of VSMC calcification.
The activation of the transcription factor NF-𝜅B is
involved in the regulation of MMP-production [28, 29] and
also VSMC calcification [30]. We here show that LOE blocks
the Ca/P-induced activation of NF-𝜅B in VSMC and also
slightly reduces its basal activity. On the one hand, this
might explain the observed effects of LOE on MMP-mRNA
expressions of MMP-2 and MMP-9 and on the other hand
might also directly contribute to attenuating effects of LOEon
VSMC calcification. The latter assumption could be deduced
from experiments where the NF-𝜅B inhibitor 17-DMAG also
directly attenuatedCa/P-induced calcifications ofVSMC [14].
Several studies deal with the isolation and structural
characterization of the active constituents from Lindera
obtusiloba [11, 12, 31]. In our group, we previously isolated
and identified the lignan (+)-episesamin in LOE [10]. A
recent study suggests that (+)-episesamin exerts protective
effects in VSMC associated cardiovascular diseases [32] and
is therefore a suitable candidate for further studies in models
of vascular calcification.
But irrespective of additional, potentially active, compo-
nents contained in LOE, the extract itself should also be tested
in animal models of vascular calcification. Herbal extracts
often contain several groups of biologically active compounds
and it is not always possible to know which compound is
responsible for the observed activities. In addition, different
groups of compounds in plant extracts may have synergistic
effects. Therefore, besides analyzing the composition and
identification of single drugs in LOE, also further testing of
the whole extract seems indicated.
5. Conclusion
In conclusion, our study demonstrates the potential of LOE
to impact the pathophysiology of vascular calcification by
affecting VSMC transdifferentiation and to inhibit MMPs
and NF-𝜅B in VSMC. Regarding the development of novel
complementary therapeutic approaches for cardiovascular
diseases, further studieswith LOEor isolated drugs fromLOE
should be performed.
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